Trial Profile
A Phase I, Dose-Ranging Safety and Immunogenicity Study of an Adenovirus-vectored Intranasal, Pandemic (Hemagglutinin H5) Influenza Vaccine, ADhVN1203/04.H5, in Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Jan 2016
Price :
$35
*
At a glance
- Drugs ADhVN120304.H5 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Adverse reactions
- Sponsors Altimmune; Vaxin
- 31 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Oct 2008 New trial record.